BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

Rosen Law Firm issued a lead-plaintiff solicitation for a previously filed securities fraud class action against Beta Bionics (NASDAQ: BBNX), with a November 3, 2026 lead plaintiff deadline covering purchasers between July 30, 2025 and February 24, 2026. The complaint alleges Beta Bionics made false statements about its iLet Bionic Pancreas insulin pump, claiming FDA Form 483 back-filed complaints numbered in the thousands and included hundreds of life-threatening hypoglycemic events, while the company failed to implement meaningful corrective actions.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.